Skip to content
Evigrade
ModerateSelective serotonin reuptake inhibitors (SSRIs)×Proton pump inhibitors

Updated · Methodology

Mechanism

Escitalopram is metabolised in the liver mainly by CYP2C19, and omeprazole inhibits this enzyme. In a study, omeprazole 30 mg once daily raised plasma escitalopram concentrations by about 50% (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, several enzymes metabolise escitalopram, so inhibiting one of them may not noticeably slow its clearance (Lexapro label, US Food and Drug Administration, FDA). A second link runs through electrolytes. Severe hypomagnesaemia has been reported in people who took omeprazole or other proton pump inhibitors for at least three months (Losec SmPC, AEMPS). Escitalopram prolongs the QT interval in a dose-dependent way, and low potassium and magnesium raise the risk of malignant arrhythmias (Cipralex SmPC, AEMPS). The documents do not describe a rise in omeprazole concentrations. According to the Spanish SmPC, escitalopram weakly inhibited CYP2C19 in vitro, so it is combined with caution with drugs metabolised by this enzyme (Cipralex SmPC, AEMPS), and omeprazole is metabolised mainly by CYP2C19 (Losec SmPC, AEMPS). According to the US label, escitalopram did not inhibit CYP2C19 in vitro (Lexapro label, FDA).

Symptoms

The documents describe no symptoms specific to this combination. As escitalopram concentrations rise, its adverse effects may increase, and these effects guide the decision to reduce the dose (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The most common are nausea and headache, followed by insomnia or drowsiness, dizziness, tremor, sweating, diarrhoea or constipation. Escitalopram prolongs the QT interval, and ventricular arrhythmias, including torsade de pointes, have been reported after marketing (Cipralex SmPC, AEMPS). Severe hypomagnesaemia with long-term omeprazole presents with fatigue, tetany, delirium, seizures, dizziness and ventricular arrhythmia, and it can begin insidiously (Losec SmPC, AEMPS).

Management

Escitalopram is used with caution together with omeprazole and other CYP2C19 inhibitors. The escitalopram dose may need to be reduced if its adverse effects increase (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When omeprazole is started or stopped, possible interactions with drugs metabolised by CYP2C19 are taken into account (Losec SmPC, AEMPS). Escitalopram is such a drug (Cipralex SmPC, AEMPS). Hypokalaemia and hypomagnesaemia are corrected before escitalopram is started, and escitalopram is used with caution together with drugs that cause them (Cipralex SmPC, AEMPS). If long-term omeprazole treatment is planned, doctors consider measuring blood magnesium before treatment and periodically afterwards (Losec SmPC, AEMPS). In people with stable heart disease, an electrocardiogram (ECG) is considered before escitalopram is started. If signs of arrhythmia appear, escitalopram is stopped and an ECG is recorded (Cipralex SmPC, AEMPS). The US labels for escitalopram and omeprazole do not name this pair (Lexapro and Prilosec labels, US Food and Drug Administration, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Escitalopram

Other interactions with Omeprazole